Azacitidine
Prefibrotic/Early Primary Myelofibrosis
M.D. Anderson Cancer CenterSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Prefibrotic/Early Primary Myelofibrosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pevonedistat M.D. Anderson Cancer Center | Phase 1/2 | CCC |
Venetoclax M.D. Anderson Cancer Center | Phase 1/2 | CCC |
TACROLIMUS City of Hope Medical Center | Phase 1 | CC |
Rapamycin City of Hope Medical Center | Phase 1 | CC |
Ruxolitinib Phosphate City of Hope Medical Center | Phase 1 | CC |
Fludarabine City of Hope Medical Center | Phase 1 | CC |
Evomela City of Hope Medical Center | Phase 1 | CC |
Same molecule, other indications
Azacitidine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
73 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →